董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel S. Janney | 男 | Director | 52 | 未披露 | 未持股 | 2018-07-31 |
| Armen B. Shanafelt | 男 | Director | 59 | 未披露 | 未持股 | 2018-07-31 |
| William J. Newell | 男 | Chief Executive Officer and Director | 61 | 70.25万美元 | 未持股 | 2018-07-31 |
| Daniel H. Petree | 男 | Director | 62 | 未披露 | 未持股 | 2018-07-31 |
| Michael Ross | 男 | Director | 69 | 未披露 | 未持股 | 2018-07-31 |
| John G. Freund | 男 | Director | 64 | 未披露 | 未持股 | 2018-07-31 |
| V. Bryan Lawlis | 男 | Director | 66 | 3.00万美元 | 未持股 | 2018-07-31 |
| Michael Ross | 男 | Director | 69 | 未披露 | 未持股 | 2018-07-31 |
| Daniel H. Petree | 男 | Director | 62 | 18.86万美元 | 未持股 | 2018-07-31 |
| Michael Dybbs | 男 | Director | 43 | 未披露 | 未持股 | 2018-07-31 |
| Joseph M. Lobacki | 男 | Director | 59 | 14.06万美元 | 未持股 | 2018-07-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William J. Newell | 男 | Chief Executive Officer and Director | 61 | 70.25万美元 | 未持股 | 2018-07-31 |
| Arturo Molina | 男 | Chief Medical Officer | 60 | 57.28万美元 | 未持股 | 2018-07-31 |
| Trevor J. Hallam | 男 | Chief Scientific Officer | 60 | 67.79万美元 | 未持股 | 2018-07-31 |
| Edward Albini | 男 | Chief Financial Officer | 61 | 未披露 | 未持股 | 2018-07-31 |
| Shabbir T. Anik | -- | Chief Technical Operations Officer | 66 | 未披露 | 未持股 | 2018-07-31 |
| Linda Fitzpatrick | 女 | Chief People and Communications Officer | 62 | 未披露 | 未持股 | 2018-07-31 |
| Stephen T. Worsley | 男 | Chief Business Officer | 55 | 未披露 | 未持股 | 2018-07-31 |
董事简历
中英对照 | 中文 | 英文- Daniel S. Janney
-
Daniel S. Janney，2007年3月起，担任本公司董事。他现为生命科学行业风投公司Alta Partners的董事总经理，他于1996年加入该公司。加入Alta Partners之前，1993-1996，他是Montgomery Securities医疗健康与生物技术投资银行部门的副总裁，专注于生命科学行业企业。他是以下公司的董事：Alba Therapeutics Corporation、DiscoveRx Corporation、Esperion Therapeutics、Prolacta Bioscience、ViroBay, Inc.他在Georgetown University获得历史学士学位，在Anderson School at the University of California, Los Angeles。获得工商管理硕士学位。
Daniel S. Janney has served as a member of our board of directors since November 2016 and is chairman of the compensation committee and a member of the audit committee. Mr. Janney is a Managing Director at Alta Partners, a life sciences venture capital firm, which he joined in 1996. Prior to joining Alta, from 1993 to 1996 he was a Vice President in Montgomery Securities’ healthcare and biotechnology investment banking group, focusing on life sciences companies. Mr. Janney is a director of a number of companies including Esperion Therapeutics NASDAQ:ESPR, Evolve Biosystems, Inc., Prolacta Bioscience, Inc., Sutro Biopharma and Viveve Medical, Inc. (NASDAQ:VIVE). He holds a Bachelor of Arts in History from Georgetown University and an M.B.A. from the Anderson School at the University of California, Los Angeles. - Daniel S. Janney，2007年3月起，担任本公司董事。他现为生命科学行业风投公司Alta Partners的董事总经理，他于1996年加入该公司。加入Alta Partners之前，1993-1996，他是Montgomery Securities医疗健康与生物技术投资银行部门的副总裁，专注于生命科学行业企业。他是以下公司的董事：Alba Therapeutics Corporation、DiscoveRx Corporation、Esperion Therapeutics、Prolacta Bioscience、ViroBay, Inc.他在Georgetown University获得历史学士学位，在Anderson School at the University of California, Los Angeles。获得工商管理硕士学位。
- Daniel S. Janney has served as a member of our board of directors since November 2016 and is chairman of the compensation committee and a member of the audit committee. Mr. Janney is a Managing Director at Alta Partners, a life sciences venture capital firm, which he joined in 1996. Prior to joining Alta, from 1993 to 1996 he was a Vice President in Montgomery Securities’ healthcare and biotechnology investment banking group, focusing on life sciences companies. Mr. Janney is a director of a number of companies including Esperion Therapeutics NASDAQ:ESPR, Evolve Biosystems, Inc., Prolacta Bioscience, Inc., Sutro Biopharma and Viveve Medical, Inc. (NASDAQ:VIVE). He holds a Bachelor of Arts in History from Georgetown University and an M.B.A. from the Anderson School at the University of California, Los Angeles.
- Armen B. Shanafelt
-
Armen B. Shanafelt， 博士-2010年1月起担任我们董事会成员。2009年4月来，Shanafelt博士一直是风险投资公司Lilly Ventures合作伙伴。加入Lilly Ventures之前，Shanafelt博士是医药研究公司，包括肿瘤学的治疗领域，内分泌和神经科学，Eli Lilly 和本公司，首席科学官负责早期的生长。Shanafelt博士目前担任上市生物科技公司Aeglea BioTherapeutics, Inc.董事会主席，并作为以下私营生物技术公司董事：Aileron Therapeutics, Surface Oncology, Sutro Biopharma, and Symic Bio Chairman。Shanafelt博士获得了 Pacific Lutheran University化学和物理学学士学位，和加州大学的化学博士学位。他在DNAX研究所完成了他的博士后工作，在那里他学习了细胞因子及其受体的结构关系。
Armen B. Shanafelt has served as a member of our board of directors since November 2010. Since April 2009 Dr. Shanafelt has served as venture partner, then general partner, of Lilly Ventures, a venture capital firm. Prior to joining Lilly Ventures, Dr. Shanafelt was one of several Chief Science Officers at Eli Lilly and Company, a pharmaceutical research company, specifically responsible for the generation of the early biotherapeutic pipeline which spanned the therapeutic areas of oncology, endocrine and neuroscience. Dr. Shanafelt serves on the boards of directors of Aeglea Biotherapeutics, Inc., Aileron Therapeutics, Inc., Protagonist Therapeutics, Inc. and Surface Oncology, Inc., as well as on the boards of directors of several private companies. Dr. Shanafelt received his B.S. in Chemistry and Physics from Pacific Lutheran University and his Ph.D. in Chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute. He is a Kauffman Fellow Class 14. - Armen B. Shanafelt， 博士-2010年1月起担任我们董事会成员。2009年4月来，Shanafelt博士一直是风险投资公司Lilly Ventures合作伙伴。加入Lilly Ventures之前，Shanafelt博士是医药研究公司，包括肿瘤学的治疗领域，内分泌和神经科学，Eli Lilly 和本公司，首席科学官负责早期的生长。Shanafelt博士目前担任上市生物科技公司Aeglea BioTherapeutics, Inc.董事会主席，并作为以下私营生物技术公司董事：Aileron Therapeutics, Surface Oncology, Sutro Biopharma, and Symic Bio Chairman。Shanafelt博士获得了 Pacific Lutheran University化学和物理学学士学位，和加州大学的化学博士学位。他在DNAX研究所完成了他的博士后工作，在那里他学习了细胞因子及其受体的结构关系。
- Armen B. Shanafelt has served as a member of our board of directors since November 2010. Since April 2009 Dr. Shanafelt has served as venture partner, then general partner, of Lilly Ventures, a venture capital firm. Prior to joining Lilly Ventures, Dr. Shanafelt was one of several Chief Science Officers at Eli Lilly and Company, a pharmaceutical research company, specifically responsible for the generation of the early biotherapeutic pipeline which spanned the therapeutic areas of oncology, endocrine and neuroscience. Dr. Shanafelt serves on the boards of directors of Aeglea Biotherapeutics, Inc., Aileron Therapeutics, Inc., Protagonist Therapeutics, Inc. and Surface Oncology, Inc., as well as on the boards of directors of several private companies. Dr. Shanafelt received his B.S. in Chemistry and Physics from Pacific Lutheran University and his Ph.D. in Chemistry from the University of California, Berkeley. He completed his postdoctoral work at DNAX Research Institute. He is a Kauffman Fellow Class 14.
- William J. Newell
-
WilliamJ.Newell自2013年11月以来一直担任我们的董事会成员。Newell自2009年2月起担任Sutro Biopharma（一家生物技术公司）首席执行官。2006年1月至2007年8月，Newell先生担任Aerovance，Inc.的总裁兼执行Vice President，该公司是一家由风险投资支持的公司，开发呼吸道疾病的临床资产。Newell先生拥有达特茅斯学院（Dartmouth College）的政府学学士学位和密歇根大学（University of Michigan）的法学博士学位。
William J. Newell has served on our board of directors since November 2013. Since February 2009 Mr. Newell has served as Chief Executive Officer at Sutro Biopharma, a biotechnology company. From January 2006 to August 2007 Mr. Newell served as President and as Executive Vice President at Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell holds an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan. - WilliamJ.Newell自2013年11月以来一直担任我们的董事会成员。Newell自2009年2月起担任Sutro Biopharma（一家生物技术公司）首席执行官。2006年1月至2007年8月，Newell先生担任Aerovance，Inc.的总裁兼执行Vice President，该公司是一家由风险投资支持的公司，开发呼吸道疾病的临床资产。Newell先生拥有达特茅斯学院（Dartmouth College）的政府学学士学位和密歇根大学（University of Michigan）的法学博士学位。
- William J. Newell has served on our board of directors since November 2013. Since February 2009 Mr. Newell has served as Chief Executive Officer at Sutro Biopharma, a biotechnology company. From January 2006 to August 2007 Mr. Newell served as President and as Executive Vice President at Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell holds an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan.
- Daniel H. Petree
-
DanielH.Petree自2009年8月以来一直担任我们的董事会成员。2012年4月，Petree先生联合创立了Four Oaks Partners Consulting，LLC，该公司为中小型生命科学公司提供交易咨询服务，2000年，Petree先生联合创立了P2Partners，LLC，Four Oaks’；同一业务的前身。在共同创立P2Partners之前，Petree先生曾担任Axys Pharmaceuticals，Inc.的总裁兼首席运营官，Arris Pharmaceuticals的执行Vice President和首席财务官，TSI Corporation的公司和业务发展Vice President，还是一名公司和证券律师。Petree先生以前曾在LPath，Inc.、Biocept，Inc.和CypressBioscience，Inc.以及一些私营生物技术公司的董事会任职。Petree先生在斯坦福大学（Stanford University）获得历史与政治学学士学位，并在密歇根大学法学院（University of Michigan Law School）获得法学博士学位。
Daniel H. Petree has served as a member of our board of directors since August 2009. In April 2012 Mr. Petree co-founded Four Oaks Partners Consulting, LLC, which provides transaction advisory services to small and medium-sized life science companies and in 2000 Mr. Petree co-founded P2 Partners, LLC, Four Oaks’ predecessor in the same business. Before co-founding P2 Partners, Mr. Petree served as President and Chief Operating Officer of Axys Pharmaceuticals, Inc., Executive Vice President and Chief Financial Officer of Arris Pharmaceuticals, Incorporated and Vice President of Business Development at TSI Corporation and was a corporate and securities lawyer. Mr. Petree previously served on the boards of directors of Lpath, Inc., Biocept, Inc. and Cypress Bioscience, Inc. along with a number of privately held biotechnology companies. Mr. Petree received an A.B. in History and Political Science from Stanford University and a J.D. from the University of Michigan Law School. - DanielH.Petree自2009年8月以来一直担任我们的董事会成员。2012年4月，Petree先生联合创立了Four Oaks Partners Consulting，LLC，该公司为中小型生命科学公司提供交易咨询服务，2000年，Petree先生联合创立了P2Partners，LLC，Four Oaks’；同一业务的前身。在共同创立P2Partners之前，Petree先生曾担任Axys Pharmaceuticals，Inc.的总裁兼首席运营官，Arris Pharmaceuticals的执行Vice President和首席财务官，TSI Corporation的公司和业务发展Vice President，还是一名公司和证券律师。Petree先生以前曾在LPath，Inc.、Biocept，Inc.和CypressBioscience，Inc.以及一些私营生物技术公司的董事会任职。Petree先生在斯坦福大学（Stanford University）获得历史与政治学学士学位，并在密歇根大学法学院（University of Michigan Law School）获得法学博士学位。
- Daniel H. Petree has served as a member of our board of directors since August 2009. In April 2012 Mr. Petree co-founded Four Oaks Partners Consulting, LLC, which provides transaction advisory services to small and medium-sized life science companies and in 2000 Mr. Petree co-founded P2 Partners, LLC, Four Oaks’ predecessor in the same business. Before co-founding P2 Partners, Mr. Petree served as President and Chief Operating Officer of Axys Pharmaceuticals, Inc., Executive Vice President and Chief Financial Officer of Arris Pharmaceuticals, Incorporated and Vice President of Business Development at TSI Corporation and was a corporate and securities lawyer. Mr. Petree previously served on the boards of directors of Lpath, Inc., Biocept, Inc. and Cypress Bioscience, Inc. along with a number of privately held biotechnology companies. Mr. Petree received an A.B. in History and Political Science from Stanford University and a J.D. from the University of Michigan Law School.
- Michael Ross
-
暂无中文简介
Michael Ross has served as a member of our board of directors since October 2006. Since 2002 Dr. Ross has served as a Managing Partner at SV Health Investors LLC, a venture capital firm. Previously, Dr. Ross served in various senior management roles at CyThera, Inc., Carta Proteomics Inc., MetaXen LLC, Arris Pharmaceuticals, Incorporated and Genentech, Inc. Dr. Ross currently serves on the boards of directors of Deciphera Pharmaceuticals, Inc., Ophthotech Corporation, Arsanis, Inc. and Catabasis Pharmaceuticals, Inc., as well on the boards of directors of Adimab Inc. and Ribometrix, Inc., both private companies. Dr. Ross is also on the Board of Overseers of the Thayer School of Engineering at Dartmouth College. Dr. Ross received an A.B. in Chemistry from Dartmouth College and a Ph.D. in Chemistry from the California Institute of Technology and completed post doctorate training in molecular biology at Harvard University. -
暂无中文简介
- Michael Ross has served as a member of our board of directors since October 2006. Since 2002 Dr. Ross has served as a Managing Partner at SV Health Investors LLC, a venture capital firm. Previously, Dr. Ross served in various senior management roles at CyThera, Inc., Carta Proteomics Inc., MetaXen LLC, Arris Pharmaceuticals, Incorporated and Genentech, Inc. Dr. Ross currently serves on the boards of directors of Deciphera Pharmaceuticals, Inc., Ophthotech Corporation, Arsanis, Inc. and Catabasis Pharmaceuticals, Inc., as well on the boards of directors of Adimab Inc. and Ribometrix, Inc., both private companies. Dr. Ross is also on the Board of Overseers of the Thayer School of Engineering at Dartmouth College. Dr. Ross received an A.B. in Chemistry from Dartmouth College and a Ph.D. in Chemistry from the California Institute of Technology and completed post doctorate training in molecular biology at Harvard University.
- John G. Freund
-
John G. Freund，他是医学博士，曾担任我们的董事会成员（2012年10月以来）。他于1997年共同创立Skyline Ventures ，并一直担任合伙人。他曾担任 Chancellor Capital Management私人股本集团（资本管理公司，一个私人资本投资公司）的常务董事。1995年，他共同创立Intuitive Surgical（一个医疗设备公司），直到2000年任职董事会。从1988年到1994年，他担任Acuson公司（超声波设备制造商，现在西门子的一部分）不同职位，最近担任执行副总裁。加入Acuson之前，他是摩根士丹利（Morgan Stanley）的普通合伙人（从1987年到1988年）。从1982年到1988年，他任职摩根士丹利（Morgan Stanley）& Co .）（一家投资银行公司），在那里他于1983年在公司财务部门共同创立医疗集团。他曾任职Concert Pharmaceuticals（一个公开上市的生物制药公司）（自2013年以来），以及，XenoPort （上市生物制药公司）（自1999年以来）。他也服务于三个美国注册投资基金的董事会，如Map Pharmaceuticals（生物制药公司），Hansen Medical（医疗设备公司）和Mako Surgical Corp（医疗设备公司）。他是哈佛商学院（Harvard Business School）的医疗计划顾问委员会成员，并且是哈佛医学院的治疗咨询委员会的成员。他获得哈佛大学的历史学士学位，哈佛医学院医学博士学位，以及哈佛商学院的工商管理硕士学位。
John G. Freund has served as a member of our Board since February 2014. Dr. Freund founded Skyline Ventures “Skyline”, a venture capital firm, in 1997 and has served as Managing Director at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, LLC. In 1995 Dr. Freund co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994 Dr. Freund served in various positions at Acuson Corporation (“Acuson”), most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a General Partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988 Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) (2012 to present) and Proteon Therapeutics, Inc. (NASDAQ: PRTO) (2014 to present), as well as on the boards of two privately held companies, Sutro Biopharma, Inc. (2014 to present) and SI-Bone, Inc. (2013 to present). Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by The Capital Group Companies. He previously served on the board of directors of several publicly traded companies, including XenoPort, Inc. (NASDAQ: XNPT) (1999 to 2016), where he was Chairman, Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (2014 to 2015), MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (2004 to 2011), and MAKO Surgical Corp. (NASDAQ: MAKO) (2008 to 2013). Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund graduated from Harvard College with a B.A. in History in 1975 received an M.D. from Harvard Medical School in 1980 and an M.B.A. from Harvard Business School in 1982. - John G. Freund，他是医学博士，曾担任我们的董事会成员（2012年10月以来）。他于1997年共同创立Skyline Ventures ，并一直担任合伙人。他曾担任 Chancellor Capital Management私人股本集团（资本管理公司，一个私人资本投资公司）的常务董事。1995年，他共同创立Intuitive Surgical（一个医疗设备公司），直到2000年任职董事会。从1988年到1994年，他担任Acuson公司（超声波设备制造商，现在西门子的一部分）不同职位，最近担任执行副总裁。加入Acuson之前，他是摩根士丹利（Morgan Stanley）的普通合伙人（从1987年到1988年）。从1982年到1988年，他任职摩根士丹利（Morgan Stanley）& Co .）（一家投资银行公司），在那里他于1983年在公司财务部门共同创立医疗集团。他曾任职Concert Pharmaceuticals（一个公开上市的生物制药公司）（自2013年以来），以及，XenoPort （上市生物制药公司）（自1999年以来）。他也服务于三个美国注册投资基金的董事会，如Map Pharmaceuticals（生物制药公司），Hansen Medical（医疗设备公司）和Mako Surgical Corp（医疗设备公司）。他是哈佛商学院（Harvard Business School）的医疗计划顾问委员会成员，并且是哈佛医学院的治疗咨询委员会的成员。他获得哈佛大学的历史学士学位，哈佛医学院医学博士学位，以及哈佛商学院的工商管理硕士学位。
- John G. Freund has served as a member of our Board since February 2014. Dr. Freund founded Skyline Ventures “Skyline”, a venture capital firm, in 1997 and has served as Managing Director at Skyline since its founding. Prior to joining Skyline, Dr. Freund served as Managing Director in the private equity group of Chancellor Capital Management, LLC. In 1995 Dr. Freund co-founded Intuitive Surgical, Inc. and served on its board of directors until 2000. From 1988 to 1994 Dr. Freund served in various positions at Acuson Corporation (“Acuson”), most recently as Executive Vice President. Prior to joining Acuson, Dr. Freund was a General Partner of Morgan Stanley Venture Partners from 1987 to 1988. From 1982 to 1988 Dr. Freund worked at Morgan Stanley & Co., where he co-founded the Healthcare Group in the Corporate Finance Department in 1983. Dr. Freund currently serves on the board of directors of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) (2012 to present) and Proteon Therapeutics, Inc. (NASDAQ: PRTO) (2014 to present), as well as on the boards of two privately held companies, Sutro Biopharma, Inc. (2014 to present) and SI-Bone, Inc. (2013 to present). Dr. Freund also serves on the board of directors of six U.S. registered investment funds managed by The Capital Group Companies. He previously served on the board of directors of several publicly traded companies, including XenoPort, Inc. (NASDAQ: XNPT) (1999 to 2016), where he was Chairman, Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (2014 to 2015), MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) (2004 to 2011), and MAKO Surgical Corp. (NASDAQ: MAKO) (2008 to 2013). Dr. Freund is a member of the Advisory Board for the Harvard Business School Healthcare Initiative. Dr. Freund graduated from Harvard College with a B.A. in History in 1975 received an M.D. from Harvard Medical School in 1980 and an M.B.A. from Harvard Business School in 1982.
- V. Bryan Lawlis
-
V. Bryan Lawlis，2012年以来，他担任Geron董事。他目前担任一家专门从事罕见遗传病生物制药公司BioMarin Pharmaceuticals，一家专门从事治疗人类疾病定制抗体的生物制药公司KaloBios Pharmaceuticals和几个私营生物技术公司的董事。Lawlis博士是一家处于早期阶段，由他2006年联合建立私营生物技术公司Itero Biopharmaceuticals的总裁兼首席执行官。Lawlis 博士2004年8月起曾担任一家专注于药物投递技术的专门药品公司Aradigm Corporation的总裁兼首席执行官，也是2005年2月以来，担任它的董事会成员，这两个职位都一直担任到2006年8月。Lawlis博士2003年6月到2004年8月担任Aradigm Corporation的总裁兼首席运营官，2001年11月到2003年6月担任它的首席运营官。之前，Lawlis博士联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并且1996年到1999年担任它的总裁兼首席执行官，1999年到2001年担任董事长，之后2001年它被卖给Akzo Nobel, NV的子公司Diosynth RTP。1981年到1996年，Lawlis博士受雇于Genencor和Genentech。他在Genentech的最后职位是工艺流程科学副总裁。Lawlis博士拥有得克萨斯大学奥斯汀分校微生物学专业学士学位，以及华盛顿州立大学生物化学专业博士学位。
V. Bryan Lawlis has served as a member of our board of directors since July 2018. Dr. Lawlis served as the President and Chief Executive Officer of Itero Holdings, LLC from 2011 to 2017 and of the predecessor company, Itero Biopharmaceuticals, Inc from 2007 to 2011 a pharmaceutical company focused on protein therapeutics. Previously, he served in various senior management positions at Aradigm Corporation, Covance Biotechnology Services, Inc. and Genentech, Inc. Dr. Lawlis is also an advisor for Phoenix Venture Partners, a venture capital firm that invests in material science and manufacturing technology. Dr. Lawlis currently serves on the boards of directors at BioMarin Pharmaceutical Inc., Geron, Inc., and Coherus Biosciences, Inc., as well as on the boards of directors of several private companies. Dr. Lawlis previously served on the boards of directors of Sutro Biopharma, Inc. and Kalobios, Inc. Dr. Lawlis holds a B.A. in Microbiology from the University of Texas at Austin and a Ph.D. in Biochemistry from Washington State University. - V. Bryan Lawlis，2012年以来，他担任Geron董事。他目前担任一家专门从事罕见遗传病生物制药公司BioMarin Pharmaceuticals，一家专门从事治疗人类疾病定制抗体的生物制药公司KaloBios Pharmaceuticals和几个私营生物技术公司的董事。Lawlis博士是一家处于早期阶段，由他2006年联合建立私营生物技术公司Itero Biopharmaceuticals的总裁兼首席执行官。Lawlis 博士2004年8月起曾担任一家专注于药物投递技术的专门药品公司Aradigm Corporation的总裁兼首席执行官，也是2005年2月以来，担任它的董事会成员，这两个职位都一直担任到2006年8月。Lawlis博士2003年6月到2004年8月担任Aradigm Corporation的总裁兼首席运营官，2001年11月到2003年6月担任它的首席运营官。之前，Lawlis博士联合创立了一家合法生物制药制造公司Covance Biotechnology Services，并且1996年到1999年担任它的总裁兼首席执行官，1999年到2001年担任董事长，之后2001年它被卖给Akzo Nobel, NV的子公司Diosynth RTP。1981年到1996年，Lawlis博士受雇于Genencor和Genentech。他在Genentech的最后职位是工艺流程科学副总裁。Lawlis博士拥有得克萨斯大学奥斯汀分校微生物学专业学士学位，以及华盛顿州立大学生物化学专业博士学位。
- V. Bryan Lawlis has served as a member of our board of directors since July 2018. Dr. Lawlis served as the President and Chief Executive Officer of Itero Holdings, LLC from 2011 to 2017 and of the predecessor company, Itero Biopharmaceuticals, Inc from 2007 to 2011 a pharmaceutical company focused on protein therapeutics. Previously, he served in various senior management positions at Aradigm Corporation, Covance Biotechnology Services, Inc. and Genentech, Inc. Dr. Lawlis is also an advisor for Phoenix Venture Partners, a venture capital firm that invests in material science and manufacturing technology. Dr. Lawlis currently serves on the boards of directors at BioMarin Pharmaceutical Inc., Geron, Inc., and Coherus Biosciences, Inc., as well as on the boards of directors of several private companies. Dr. Lawlis previously served on the boards of directors of Sutro Biopharma, Inc. and Kalobios, Inc. Dr. Lawlis holds a B.A. in Microbiology from the University of Texas at Austin and a Ph.D. in Biochemistry from Washington State University.
- Michael Ross
-
Michael Ross，他是哲学博士。他担任我们的董事（2013年5月以来）。他曾一直担任SV Life Sciences公司（风险资本公司）的执行合伙人（自2001年1月以来）。他也曾担任Didyma公司（生物技术管理咨询公司）的执行合伙人（从1999年到2002年）。此前，他曾担任CyThera公司、 Carta Proteomics 公司、MetaXen公司和Arris Pharmaceutical Corporation的首席执行官。职业生涯早期，他任职于Genentech公司，担任多种职务，包括开发副总裁和药用化学、生物分子副总裁。他曾任职于Arris Pharmaceutical Corporation 和Archemix公司的董事会成员，以及达特茅斯学院塞耶工程学院（ the Thayer School of Engineering at Dartmouth College）的董事会成员。他持有Dartmouth College的学士学位，以及 the California Institute of Technology的哲学博士学位。他也完成了哈佛大学（Harvard University）的分子生物学博士后培训。
Michael Ross has served as a member of our board of directors since February 2011. Additionally, he has served as a Managing Partner at SV Health Investors, LLC, a venture capital investment advisory firm, since 2002 where he also served as a Venture Partner from 2001 until 2002. Prior to joining SV Health Investors, Dr. Ross served at Genentech for 13 years in roles of increasing responsibility, including as its Vice President of Drug Development. Dr. Ross was also the founder and served as Chief Executive Officer of numerous biotechnology companies such as Arris Pharmaceutical, MetaXen, ExSAR and CyThera now Viacyte. Additionally, Dr. Ross served as a Managing Partner for Didyma, LLC, a biotechnology management consulting firm, and served on the boards of directors of Cartar Proteomics, Epimmune, Genencor, MetaXen and Xenova. Dr. Ross currently serves on the boards of directors of Catabasis Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where he has served since April 2010 and Ophthotech Corporation, a publicly traded biopharmaceutical company, where he has served since April 2013. Dr. Ross earned his B.A. in Chemistry from Dartmouth College and his Ph.D. in Chemistry from the California Institute of Technology. He later held an NIH Postdoctoral Fellowship in Molecular Biology at Harvard. - Michael Ross，他是哲学博士。他担任我们的董事（2013年5月以来）。他曾一直担任SV Life Sciences公司（风险资本公司）的执行合伙人（自2001年1月以来）。他也曾担任Didyma公司（生物技术管理咨询公司）的执行合伙人（从1999年到2002年）。此前，他曾担任CyThera公司、 Carta Proteomics 公司、MetaXen公司和Arris Pharmaceutical Corporation的首席执行官。职业生涯早期，他任职于Genentech公司，担任多种职务，包括开发副总裁和药用化学、生物分子副总裁。他曾任职于Arris Pharmaceutical Corporation 和Archemix公司的董事会成员，以及达特茅斯学院塞耶工程学院（ the Thayer School of Engineering at Dartmouth College）的董事会成员。他持有Dartmouth College的学士学位，以及 the California Institute of Technology的哲学博士学位。他也完成了哈佛大学（Harvard University）的分子生物学博士后培训。
- Michael Ross has served as a member of our board of directors since February 2011. Additionally, he has served as a Managing Partner at SV Health Investors, LLC, a venture capital investment advisory firm, since 2002 where he also served as a Venture Partner from 2001 until 2002. Prior to joining SV Health Investors, Dr. Ross served at Genentech for 13 years in roles of increasing responsibility, including as its Vice President of Drug Development. Dr. Ross was also the founder and served as Chief Executive Officer of numerous biotechnology companies such as Arris Pharmaceutical, MetaXen, ExSAR and CyThera now Viacyte. Additionally, Dr. Ross served as a Managing Partner for Didyma, LLC, a biotechnology management consulting firm, and served on the boards of directors of Cartar Proteomics, Epimmune, Genencor, MetaXen and Xenova. Dr. Ross currently serves on the boards of directors of Catabasis Pharmaceuticals, Inc., a publicly traded pharmaceutical company, where he has served since April 2010 and Ophthotech Corporation, a publicly traded biopharmaceutical company, where he has served since April 2013. Dr. Ross earned his B.A. in Chemistry from Dartmouth College and his Ph.D. in Chemistry from the California Institute of Technology. He later held an NIH Postdoctoral Fellowship in Molecular Biology at Harvard.
- Daniel H. Petree
-
Daniel H. Petree，2008年11月以来，他担任Lpath的董事。2010年9月他被任命为董事长。他在生物工程工业有超过20年的经验，他担任各种职位，包括投资银行家，高级运营经理以及公司和证券律师。他是P2 Partners, LLC（2000年创办）成员和联合创始人和Four Oaks Partners Consulting, LLC（2012年4月创立）的联合创始人。2个公司为中小型科技企业提供交易谘询服务。从2004年到2011年，他担任Cypress Biosciences, Inc.（为患者提供治疗功能性躯体症状和其他中枢神经系统疾病的产品的公司）的董事。2000年联合创办P2 Partners之前，他曾是Axys Pharmaceutical（南圣弗朗西斯科的基于结构的药物设计公司）的总裁兼首席运营官。他在斯坦福大学(Stanford University)获得历史和政治科学学士学位，在密歇根大学(University of Michigan)法学院获得法学博士学位。
Daniel H. Petree has served as a director of Lpath since November 2008 and was appointed as Chairman of the Board in September 2010. Mr. Petree is a member and co-founder of P2 Partners, LLC formed in 2000 and a member and co-founder of Four Oaks Partners Consulting, LLC, founded in April 2012 both of which provide transaction advisory services to small and medium-sized science companies. Mr. Petree served as a director and chairman of the audit committee of Cypress Biosciences, Inc., a company that provides products for the treatment of patients with Functional Somatic Syndromes and other central nervous system disorders from 2004 to 2010. Before co-founding P2 Partners in 2000 Mr. Petree was President and Chief Operating Officer of Axys Pharmaceuticals, a structure-based drug design company in South San Francisco. - Daniel H. Petree，2008年11月以来，他担任Lpath的董事。2010年9月他被任命为董事长。他在生物工程工业有超过20年的经验，他担任各种职位，包括投资银行家，高级运营经理以及公司和证券律师。他是P2 Partners, LLC（2000年创办）成员和联合创始人和Four Oaks Partners Consulting, LLC（2012年4月创立）的联合创始人。2个公司为中小型科技企业提供交易谘询服务。从2004年到2011年，他担任Cypress Biosciences, Inc.（为患者提供治疗功能性躯体症状和其他中枢神经系统疾病的产品的公司）的董事。2000年联合创办P2 Partners之前，他曾是Axys Pharmaceutical（南圣弗朗西斯科的基于结构的药物设计公司）的总裁兼首席运营官。他在斯坦福大学(Stanford University)获得历史和政治科学学士学位，在密歇根大学(University of Michigan)法学院获得法学博士学位。
- Daniel H. Petree has served as a director of Lpath since November 2008 and was appointed as Chairman of the Board in September 2010. Mr. Petree is a member and co-founder of P2 Partners, LLC formed in 2000 and a member and co-founder of Four Oaks Partners Consulting, LLC, founded in April 2012 both of which provide transaction advisory services to small and medium-sized science companies. Mr. Petree served as a director and chairman of the audit committee of Cypress Biosciences, Inc., a company that provides products for the treatment of patients with Functional Somatic Syndromes and other central nervous system disorders from 2004 to 2010. Before co-founding P2 Partners in 2000 Mr. Petree was President and Chief Operating Officer of Axys Pharmaceuticals, a structure-based drug design company in South San Francisco.
- Michael Dybbs
-
Michael Dybbs， 他是哲学博士。他担任我们的董事（2013年3月以来）。他目前担任New Leaf公司（他于2009年5月加入该公司）的负责人。加入 New Leaf公司之前，他曾担任波士顿咨询集团（the Boston Consulting Group）的负责人（从2005年到2009年）。他目前任职于 Advanced Cell Diagnostics公司的董事会。他持有哈佛大学（Harvard University）的生化科学学士学位，以及加州大学伯克利分校（the University of California, Berkeley）的分子生物学和遗传学博士学位。
Michael Dybbs has served on our board of directors since August 2019. Dr. Dybbs is currently a partner at Samsara BioCapital, where he has worked since March 2017. Prior to joining Samsara, Dr. Dybbs was a partner at New Leaf Venture Partners, L.L.C., where he worked from May 2009 until September 2016. Before joining New Leaf Venture Partners, L.L.C., Dr. Dybbs was a principal at the Boston Consulting Group. Dr. Dybbs currently serves on the board of Sutro Biopharma, Inc. and as a director of several private companies. Dr. Dybbs previously served on the boards of directors of Versartis, Inc. and Dimension Therapeutics, Inc. Dr. Dybbs received an A.B. in biochemical sciences from Harvard College and a Ph.D. in molecular biology from the University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship. - Michael Dybbs， 他是哲学博士。他担任我们的董事（2013年3月以来）。他目前担任New Leaf公司（他于2009年5月加入该公司）的负责人。加入 New Leaf公司之前，他曾担任波士顿咨询集团（the Boston Consulting Group）的负责人（从2005年到2009年）。他目前任职于 Advanced Cell Diagnostics公司的董事会。他持有哈佛大学（Harvard University）的生化科学学士学位，以及加州大学伯克利分校（the University of California, Berkeley）的分子生物学和遗传学博士学位。
- Michael Dybbs has served on our board of directors since August 2019. Dr. Dybbs is currently a partner at Samsara BioCapital, where he has worked since March 2017. Prior to joining Samsara, Dr. Dybbs was a partner at New Leaf Venture Partners, L.L.C., where he worked from May 2009 until September 2016. Before joining New Leaf Venture Partners, L.L.C., Dr. Dybbs was a principal at the Boston Consulting Group. Dr. Dybbs currently serves on the board of Sutro Biopharma, Inc. and as a director of several private companies. Dr. Dybbs previously served on the boards of directors of Versartis, Inc. and Dimension Therapeutics, Inc. Dr. Dybbs received an A.B. in biochemical sciences from Harvard College and a Ph.D. in molecular biology from the University of California, Berkeley, where he was awarded a Howard Hughes Medical Institute fellowship.
- Joseph M. Lobacki
-
Joseph M. Lobacki自2013年12月起出任本公司董事。自2012年起出任本公司独立生物技术顾问。最近担任Idera Pharmaceuticals。的肿瘤总经理。从2011至2012年Amgen公司收购之前，担任Micromet, Inc.的高级副总裁兼首席商务官。曾在多个生命科学公司担任要职，包括MICROMET公司，Genzyme公司，SangStat医药公司，Cell Pathways公司，Rhone-Poulenc Rorer and Lederle实验室。 自2003年至2011年在Genzyme公司担任资深副总裁兼总经理，负责美国移植和肿瘤；高级副总裁兼总经理，负责全球移植和肿瘤；高级副总裁兼总经理，负责全球移植。在60多个国家执导Genzyme公司价值6.5亿美元的全球血液和器官移植业务的整体策略，全权负责占全球收入超过50%的美国业务。获得波士顿学院的理学士学位和麻省理工学院的药物学理学士。在治疗肿瘤性疾病的新方法上，拥有多项已发行和正在申请的专利。
Joseph M. Lobacki has served as a member of our board of directors since February 2017. Since January 2018 Mr. Lobacki has served as Executive Vice President and Chief Commercial Officer for Verastem Oncology, a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of hematologic malignancies. From November 2016 to December 2017 Mr. Lobacki served as Chief Operating Officer for Crestovo, a clinical-stage biopharmaceutical company focused on microbiome therapies. From 2014 to 2016 Mr. Lobacki served as Chief Commercial Officer at Medivation, Inc., a biopharmaceutical company focused on development of novel therapies for the treatment of serious diseases. From 2012 to 2014 Mr. Lobacki also served as General Manager of Oncology and an independent biotechnology consultant at Idera Pharmaceuticals, Inc., a biopharmaceutical company focused on therapies for cancer and rare diseases. Previously, Mr. Lobacki served as Senior Vice-President and Chief Commercial Officer at Micromet, Inc., Senior Vice-President and General Manager of US Transplant and Oncology at Genzyme Corporation and in various other positions at SangStat Medical Corporation, Cell Pathways, Inc., Rhone-Poulenc Rorer and Lederle Laboratories. Mr. Lobacki previously served on the board of directors of Celator Pharmaceuticals Inc. Mr. Lobacki earned a B.S. in Biology from Boston College and a B.S. in Pharmacy from the Massachusetts College of Pharmacy. - Joseph M. Lobacki自2013年12月起出任本公司董事。自2012年起出任本公司独立生物技术顾问。最近担任Idera Pharmaceuticals。的肿瘤总经理。从2011至2012年Amgen公司收购之前，担任Micromet, Inc.的高级副总裁兼首席商务官。曾在多个生命科学公司担任要职，包括MICROMET公司，Genzyme公司，SangStat医药公司，Cell Pathways公司，Rhone-Poulenc Rorer and Lederle实验室。 自2003年至2011年在Genzyme公司担任资深副总裁兼总经理，负责美国移植和肿瘤；高级副总裁兼总经理，负责全球移植和肿瘤；高级副总裁兼总经理，负责全球移植。在60多个国家执导Genzyme公司价值6.5亿美元的全球血液和器官移植业务的整体策略，全权负责占全球收入超过50%的美国业务。获得波士顿学院的理学士学位和麻省理工学院的药物学理学士。在治疗肿瘤性疾病的新方法上，拥有多项已发行和正在申请的专利。
- Joseph M. Lobacki has served as a member of our board of directors since February 2017. Since January 2018 Mr. Lobacki has served as Executive Vice President and Chief Commercial Officer for Verastem Oncology, a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of hematologic malignancies. From November 2016 to December 2017 Mr. Lobacki served as Chief Operating Officer for Crestovo, a clinical-stage biopharmaceutical company focused on microbiome therapies. From 2014 to 2016 Mr. Lobacki served as Chief Commercial Officer at Medivation, Inc., a biopharmaceutical company focused on development of novel therapies for the treatment of serious diseases. From 2012 to 2014 Mr. Lobacki also served as General Manager of Oncology and an independent biotechnology consultant at Idera Pharmaceuticals, Inc., a biopharmaceutical company focused on therapies for cancer and rare diseases. Previously, Mr. Lobacki served as Senior Vice-President and Chief Commercial Officer at Micromet, Inc., Senior Vice-President and General Manager of US Transplant and Oncology at Genzyme Corporation and in various other positions at SangStat Medical Corporation, Cell Pathways, Inc., Rhone-Poulenc Rorer and Lederle Laboratories. Mr. Lobacki previously served on the board of directors of Celator Pharmaceuticals Inc. Mr. Lobacki earned a B.S. in Biology from Boston College and a B.S. in Pharmacy from the Massachusetts College of Pharmacy.
高管简历
中英对照 | 中文 | 英文- William J. Newell
WilliamJ.Newell自2013年11月以来一直担任我们的董事会成员。Newell自2009年2月起担任Sutro Biopharma（一家生物技术公司）首席执行官。2006年1月至2007年8月，Newell先生担任Aerovance，Inc.的总裁兼执行Vice President，该公司是一家由风险投资支持的公司，开发呼吸道疾病的临床资产。Newell先生拥有达特茅斯学院（Dartmouth College）的政府学学士学位和密歇根大学（University of Michigan）的法学博士学位。
William J. Newell has served on our board of directors since November 2013. Since February 2009 Mr. Newell has served as Chief Executive Officer at Sutro Biopharma, a biotechnology company. From January 2006 to August 2007 Mr. Newell served as President and as Executive Vice President at Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell holds an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan.- WilliamJ.Newell自2013年11月以来一直担任我们的董事会成员。Newell自2009年2月起担任Sutro Biopharma（一家生物技术公司）首席执行官。2006年1月至2007年8月，Newell先生担任Aerovance，Inc.的总裁兼执行Vice President，该公司是一家由风险投资支持的公司，开发呼吸道疾病的临床资产。Newell先生拥有达特茅斯学院（Dartmouth College）的政府学学士学位和密歇根大学（University of Michigan）的法学博士学位。
- William J. Newell has served on our board of directors since November 2013. Since February 2009 Mr. Newell has served as Chief Executive Officer at Sutro Biopharma, a biotechnology company. From January 2006 to August 2007 Mr. Newell served as President and as Executive Vice President at Aerovance, Inc., a venture-backed company developing clinical assets for respiratory diseases. Mr. Newell holds an A.B. in Government from Dartmouth College and a J.D. from the University of Michigan.
- Arturo Molina
Arturo Molina自2016年2月起担任我们的首席医疗官。2013年2月至2016年2月，莫利纳博士担任加州创新中心（强生公司&8217；s California Innovation Center）肿瘤学科学创新Vice President，该组织专注于与新兴公司建立早期合作。此前，莫利纳博士曾担任强生公司（Johnson and Johnson&8217；s Ortho Biotech Oncology研究与开发）的首席医疗官兼临床开发Vice President，该公司是美洲狮生物技术公司（Cougar Biotechnology，Inc.）的子公司，Biogen Idec，Inc.医学研究和临床开发部肿瘤学/血液学高级主管和临时主管，以及Idec Pharmaceuticals Corporation医疗事务高级主管。Molina自2006年起担任Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program国家顾问委员会成员。Molina从1991年到2002年担任City of Hope Comprehensive Cancer Center血液学/骨髓移植和医疗肿瘤学/治疗学研究部教员，从2004年到2007年担任兼职教授。Molina博士还曾在City of Hope Medical Group的董事会任职。Molina博士在德克萨斯大学奥斯汀分校（University of Texas at Austin）获得动物学学士学位和心理学学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得生理学硕士学位和医学博士学位。他获得内科和医疗肿瘤学的董事会认证，拥有活跃的加州医疗执照，是退伍军人事务帕洛阿尔托医疗保健系统肿瘤诊所的工作人员医师志愿者。
Arturo Molina has served as our Chief Medical Officer since February 2016. From February 2013 to February 2016 Dr. Molina served as Vice President of Oncology Scientific Innovation at Johnson & Johnson’s California Innovation Center, an organization focused on building early stage collaborations with emerging companies. Previously, Dr. Molina served as Chief Medical Officer and Vice President of Clinical Development for Johnson and Johnson’s Ortho Biotech Oncology Research and Development, a unit of Cougar Biotechnology, Inc., Chief Medical Officer of Cougar Biotechnology, Inc., Senior Director and Interim Head of Oncology/Hematology in the Department of Medical Research and Clinical Development at Biogen Idec, Inc., and Senior Director of Medical Affairs at IDEC Pharmaceuticals Corporation. Since 2006 Dr. Molina has served as a National Advisory Committee Member for the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. From 1991 to 2002 Dr. Molina was a faculty staff physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center and Adjunct Professor from 2004 to 2007. Dr. Molina was also on the Board of Directors of the City of Hope Medical Group. Dr. Molina received a B.S. in Zoology and B.A. in Psychology from the University of Texas at Austin and an M.S. in Physiology and M.D. from Stanford University School of Medicine. He is board certified in internal medicine and medical oncology, has an active California medical license and is a staff physician volunteer in the Oncology Clinic at the Veterans Affairs Palo Alto Health Care System.- Arturo Molina自2016年2月起担任我们的首席医疗官。2013年2月至2016年2月，莫利纳博士担任加州创新中心（强生公司&8217；s California Innovation Center）肿瘤学科学创新Vice President，该组织专注于与新兴公司建立早期合作。此前，莫利纳博士曾担任强生公司（Johnson and Johnson&8217；s Ortho Biotech Oncology研究与开发）的首席医疗官兼临床开发Vice President，该公司是美洲狮生物技术公司（Cougar Biotechnology，Inc.）的子公司，Biogen Idec，Inc.医学研究和临床开发部肿瘤学/血液学高级主管和临时主管，以及Idec Pharmaceuticals Corporation医疗事务高级主管。Molina自2006年起担任Robert Wood Johnson Foundation Harold Amos Medical Faculty Development Program国家顾问委员会成员。Molina从1991年到2002年担任City of Hope Comprehensive Cancer Center血液学/骨髓移植和医疗肿瘤学/治疗学研究部教员，从2004年到2007年担任兼职教授。Molina博士还曾在City of Hope Medical Group的董事会任职。Molina博士在德克萨斯大学奥斯汀分校（University of Texas at Austin）获得动物学学士学位和心理学学士学位，在斯坦福大学医学院（Stanford University School of Medicine）获得生理学硕士学位和医学博士学位。他获得内科和医疗肿瘤学的董事会认证，拥有活跃的加州医疗执照，是退伍军人事务帕洛阿尔托医疗保健系统肿瘤诊所的工作人员医师志愿者。
- Arturo Molina has served as our Chief Medical Officer since February 2016. From February 2013 to February 2016 Dr. Molina served as Vice President of Oncology Scientific Innovation at Johnson & Johnson’s California Innovation Center, an organization focused on building early stage collaborations with emerging companies. Previously, Dr. Molina served as Chief Medical Officer and Vice President of Clinical Development for Johnson and Johnson’s Ortho Biotech Oncology Research and Development, a unit of Cougar Biotechnology, Inc., Chief Medical Officer of Cougar Biotechnology, Inc., Senior Director and Interim Head of Oncology/Hematology in the Department of Medical Research and Clinical Development at Biogen Idec, Inc., and Senior Director of Medical Affairs at IDEC Pharmaceuticals Corporation. Since 2006 Dr. Molina has served as a National Advisory Committee Member for the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. From 1991 to 2002 Dr. Molina was a faculty staff physician in the Department of Hematology/Bone Marrow Transplantation and Department of Medical Oncology/Therapeutics Research at City of Hope Comprehensive Cancer Center and Adjunct Professor from 2004 to 2007. Dr. Molina was also on the Board of Directors of the City of Hope Medical Group. Dr. Molina received a B.S. in Zoology and B.A. in Psychology from the University of Texas at Austin and an M.S. in Physiology and M.D. from Stanford University School of Medicine. He is board certified in internal medicine and medical oncology, has an active California medical license and is a staff physician volunteer in the Oncology Clinic at the Veterans Affairs Palo Alto Health Care System.
- Trevor J. Hallam
TrevorJ.Hallam自2010年12月以来一直担任我们的首席科学官。在加入我们之前，Hallam博士是PalatinTechnologies，Inc.研发部门的执行Vice President，并在多家制药公司担任过多个高级管理职位，包括AstraZeneca PLC、SmithKline&French Laboratories，Ltd.、葛兰素集团研究有限公司、罗氏研究公司和罗纳普朗克制药公司。Hallam博士在利兹大学（University of Leeds）获得生物化学理学学士学位，在伦敦大学（University of London）国王学院（Kings College）获得生物化学博士学位。随后，他在剑桥大学生理实验室进行博士后培训。
Trevor J. Hallam has served as our Chief Science Officer since December 2010. Prior to joining us, Dr. Hallam was Executive Vice President of Research & Development at Palatin Technologies, Inc., and held several senior management positions in various pharmaceutical companies, including AstraZeneca PLC, SmithKline & French Laboratories, Ltd., Glaxo Group Research Ltd., Roche Research and Rhone-Poulenc Rorer. Dr. Hallam received a BSc Hons in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge.- TrevorJ.Hallam自2010年12月以来一直担任我们的首席科学官。在加入我们之前，Hallam博士是PalatinTechnologies，Inc.研发部门的执行Vice President，并在多家制药公司担任过多个高级管理职位，包括AstraZeneca PLC、SmithKline&French Laboratories，Ltd.、葛兰素集团研究有限公司、罗氏研究公司和罗纳普朗克制药公司。Hallam博士在利兹大学（University of Leeds）获得生物化学理学学士学位，在伦敦大学（University of London）国王学院（Kings College）获得生物化学博士学位。随后，他在剑桥大学生理实验室进行博士后培训。
- Trevor J. Hallam has served as our Chief Science Officer since December 2010. Prior to joining us, Dr. Hallam was Executive Vice President of Research & Development at Palatin Technologies, Inc., and held several senior management positions in various pharmaceutical companies, including AstraZeneca PLC, SmithKline & French Laboratories, Ltd., Glaxo Group Research Ltd., Roche Research and Rhone-Poulenc Rorer. Dr. Hallam received a BSc Hons in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge.
- Edward Albini
Edward Albini自2013年1月以来一直担任我们的首席财务官。2012年期间，Albini先生担任Carbylan Biosurgery的咨询首席财务官，该公司专注于先进的基于生物材料的联合疗法的开发和商业化。从2011年到2016年，阿尔比尼还担任Itero Holdings，LLC的首席财务官和秘书，Itero Holdings，LLC是Itero Biopharmaceuticals，Inc.的继任实体，Itero Biopharmaceuticals，Inc.专注于蛋白质疗法的开发和商业化，2009年至2011年，阿尔比尼先生担任首席财务官和高级副总裁。此前，Albini先生曾担任Novacea，Inc.和Lynx Therapeutics，Inc.的首席财务官，这两家公司都是生物制药公司。Albini先生在圣克拉拉大学（Santa Clara University）获得会计学学士学位，并在加州大学伯克利分校（University of California，Berkeley）沃尔特·哈斯商学院（Walter A.Haas School of Business）获得工商管理硕士学位。Albini先生也是加州的一名注册会计师非活跃状态。
Edward Albini has served as our Chief Financial Officer since January 2013. During 2012 Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016 Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini received a B.S.C. in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant inactive status in California.- Edward Albini自2013年1月以来一直担任我们的首席财务官。2012年期间，Albini先生担任Carbylan Biosurgery的咨询首席财务官，该公司专注于先进的基于生物材料的联合疗法的开发和商业化。从2011年到2016年，阿尔比尼还担任Itero Holdings，LLC的首席财务官和秘书，Itero Holdings，LLC是Itero Biopharmaceuticals，Inc.的继任实体，Itero Biopharmaceuticals，Inc.专注于蛋白质疗法的开发和商业化，2009年至2011年，阿尔比尼先生担任首席财务官和高级副总裁。此前，Albini先生曾担任Novacea，Inc.和Lynx Therapeutics，Inc.的首席财务官，这两家公司都是生物制药公司。Albini先生在圣克拉拉大学（Santa Clara University）获得会计学学士学位，并在加州大学伯克利分校（University of California，Berkeley）沃尔特·哈斯商学院（Walter A.Haas School of Business）获得工商管理硕士学位。Albini先生也是加州的一名注册会计师非活跃状态。
- Edward Albini has served as our Chief Financial Officer since January 2013. During 2012 Mr. Albini served as a consulting Chief Financial Officer for Carbylan Biosurgery, a company focused on the development and commercialization of advanced biomaterial-based joint therapies. From 2011 to 2016 Mr. Albini also served as Chief Financial Officer and Secretary for Itero Holdings, LLC, a successor entity to Itero Biopharmaceuticals, Inc., a company focused on the development and commercialization of protein therapeutics, at which Mr. Albini served as Chief Financial Officer and Senior Vice President from 2009 to 2011. Previously, Mr. Albini served as Chief Financial Officer of Novacea, Inc. and Lynx Therapeutics, Inc., both biopharmaceutical companies. Mr. Albini received a B.S.C. in Accounting from Santa Clara University and an M.B.A. from the Walter A. Haas School of Business at the University of California, Berkeley. Mr. Albini is also a certified public accountant inactive status in California.
- Shabbir T. Anik
ShabbirT.Anik自2016年3月起担任我们的首席技术运营官。2011年8月至2015年12月，Anik博士担任OnyxPharmaceuticals，Inc.的技术运营高级副总裁，该公司是一家专注于开发治疗癌症药物的制药公司。此前，Anik博士曾担任Althea Technologies Inc.的总裁兼首席执行官，Patheon Inc.的全球药物开发服务总裁兼首席科学官，并在Neurex Corporation和Syntex Inc.担任多个领导职位。Anik博士在孟买大学（University of Bombay）获得药学学士学位，在威斯康星大学麦迪逊分校（University of Wisconsin，Madison）获得药学博士学位，在圣克拉拉大学（Santa Clara University）获得工商管理硕士学位。
Shabbir T. Anik has served as our Chief Technical Operations Officer since March 2016. From August 2011 to December 2015 Dr. Anik served as Senior Vice President of Technical Operations at Onyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing medicines for the treatment of cancer. Previously, Dr. Anik served as President and Chief Executive Officer of Althea Technologies Inc., President of Global Pharmaceutical Development Services and Chief Scientific Officer for Patheon Inc. and in various leadership positions at Neurex Corporation and Syntex Inc. Dr. Anik received a B.S. in Pharmacy from the University of Bombay, a Ph.D. in Pharmaceutical Sciences from the University of Wisconsin, Madison and an M.B.A. from Santa Clara University.- ShabbirT.Anik自2016年3月起担任我们的首席技术运营官。2011年8月至2015年12月，Anik博士担任OnyxPharmaceuticals，Inc.的技术运营高级副总裁，该公司是一家专注于开发治疗癌症药物的制药公司。此前，Anik博士曾担任Althea Technologies Inc.的总裁兼首席执行官，Patheon Inc.的全球药物开发服务总裁兼首席科学官，并在Neurex Corporation和Syntex Inc.担任多个领导职位。Anik博士在孟买大学（University of Bombay）获得药学学士学位，在威斯康星大学麦迪逊分校（University of Wisconsin，Madison）获得药学博士学位，在圣克拉拉大学（Santa Clara University）获得工商管理硕士学位。
- Shabbir T. Anik has served as our Chief Technical Operations Officer since March 2016. From August 2011 to December 2015 Dr. Anik served as Senior Vice President of Technical Operations at Onyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing medicines for the treatment of cancer. Previously, Dr. Anik served as President and Chief Executive Officer of Althea Technologies Inc., President of Global Pharmaceutical Development Services and Chief Scientific Officer for Patheon Inc. and in various leadership positions at Neurex Corporation and Syntex Inc. Dr. Anik received a B.S. in Pharmacy from the University of Bombay, a Ph.D. in Pharmaceutical Sciences from the University of Wisconsin, Madison and an M.B.A. from Santa Clara University.
- Linda Fitzpatrick
Linda Fitzpatrick自2018年8月起担任我们的首席人力和通信官。从2008年1月至2018年8月，Fitzpatrick女士以高级顾问的身份担任我们的人力资源和沟通副总裁。除了她的战略咨询实践，她于2002年4月共同创立Parallax Venture Partners公司（早期医疗保健风险基金）。从1992年10月到2002年3月，菲茨帕特里克女士担任吉利德科学公司公司人力资源、企业沟通与运营Vice President，从1985年2月到1992年9月，她担任Genentech，Inc.公司投资者关系总监兼薪酬、福利与系统总监，除了领导各种上市生物技术公司的人力资源和企业传播战略。Fitzpatrick女士还在科学，教育和社区发展领域的各种非营利董事会任职，包括担任董事会主席。Fitzpatrick女士在旧金山州立大学（San Francisco State University）获得心理学和社会学学士学位。
Linda Fitzpatrick has served as our Chief People and Communications Officer since August 2018. From January 2008 to August 2018 Ms. Fitzpatrick served as our VP of Human Resources and Communications in the capacity of Senior Advisor. In addition to her strategic consulting practice, she co-founded Parallax Venture Partners, an early stage health care venture fund in April 2002. From October 1992 to March 2002 Ms. Fitzpatrick served as Vice President of Human Resources, Corporate Communications and Operations for Gilead Sciences, Inc. and from February 1985 to September 1992 she served as Director of Investor Relations and Director of Compensation, Benefits and Systems for Genentech, Inc., in addition to heading the human resources and corporate communications strategy for a variety of publicly held biotechnology companies. Ms. Fitzpatrick also serves on a variety of non-profit boards, including board chair roles, in the science, education and community development arenas. Ms. Fitzpatrick received a B.A. in Psychology and Sociology from San Francisco State University.- Linda Fitzpatrick自2018年8月起担任我们的首席人力和通信官。从2008年1月至2018年8月，Fitzpatrick女士以高级顾问的身份担任我们的人力资源和沟通副总裁。除了她的战略咨询实践，她于2002年4月共同创立Parallax Venture Partners公司（早期医疗保健风险基金）。从1992年10月到2002年3月，菲茨帕特里克女士担任吉利德科学公司公司人力资源、企业沟通与运营Vice President，从1985年2月到1992年9月，她担任Genentech，Inc.公司投资者关系总监兼薪酬、福利与系统总监，除了领导各种上市生物技术公司的人力资源和企业传播战略。Fitzpatrick女士还在科学，教育和社区发展领域的各种非营利董事会任职，包括担任董事会主席。Fitzpatrick女士在旧金山州立大学（San Francisco State University）获得心理学和社会学学士学位。
- Linda Fitzpatrick has served as our Chief People and Communications Officer since August 2018. From January 2008 to August 2018 Ms. Fitzpatrick served as our VP of Human Resources and Communications in the capacity of Senior Advisor. In addition to her strategic consulting practice, she co-founded Parallax Venture Partners, an early stage health care venture fund in April 2002. From October 1992 to March 2002 Ms. Fitzpatrick served as Vice President of Human Resources, Corporate Communications and Operations for Gilead Sciences, Inc. and from February 1985 to September 1992 she served as Director of Investor Relations and Director of Compensation, Benefits and Systems for Genentech, Inc., in addition to heading the human resources and corporate communications strategy for a variety of publicly held biotechnology companies. Ms. Fitzpatrick also serves on a variety of non-profit boards, including board chair roles, in the science, education and community development arenas. Ms. Fitzpatrick received a B.A. in Psychology and Sociology from San Francisco State University.
- Stephen T. Worsley
StephenT.Worsley自2018年9月起担任我们的首席商务官。从2017年10月至2018年9月，Worsley先生担任Sr.Vice President，INDI Molecular，Inc.的业务开发，该公司是一家新兴的生命科学公司，开发一类合成的诊断和治疗剂。2013年11月至2017年10月，Worsley先生担任Peregrine Pharmaceutical，Inc.（现Avid BioServices，Inc.）的业务发展Vice President，该公司是一家生物制药公司，开发免疫肿瘤相关抗体并制造生物制药产品。在加入Peregrine之前，Worsley先生曾在多家制药公司担任多个高级管理职位，其中包括Centrose Pharmaceutical，Inc.、Intrexon Corporation、Raven Biotechnologies，Inc.和Abgenix，Inc.。Worsley先生此前还曾在Peregrine Beijing，Ltd.的董事会任职。Worsley先生在犹他大学（University of Utah）获得国际经济与金融学学士学位，并在华盛顿大学（University of Washington）获得金融学工商管理硕士学位。
Stephen T. Worsley has served as our Chief Business Officer since September 2018. From October 2017 to September 2018 Mr. Worsley served as Sr. Vice President, Business Development for Indi Molecular, Inc., an emerging life sciences company developing a synthetic class of diagnostic and therapeutic agents. From November 2013 to October 2017 Mr. Worsley served as Vice President of Business Development for Peregrine Pharmaceutical, Inc., now Avid BioServices, Inc, a biopharmaceutical company developing immuno-oncology related antibodies and manufacturing of biopharmaceutical products. Prior to Peregrine, Mr. Worsley held several senior management positions in various pharmaceutical companies, including Centrose Pharmaceutical, Inc., Intrexon Corporation, Raven Biotechnologies, Inc. and Abgenix, Inc. Mr. Worsley also previously served on the Board of Directors of Peregrine Beijing, Ltd. Mr. Worsley received a B.S. in International Economics and Finance from the University of Utah and an M.B.A. in Finance from the University of Washington.- StephenT.Worsley自2018年9月起担任我们的首席商务官。从2017年10月至2018年9月，Worsley先生担任Sr.Vice President，INDI Molecular，Inc.的业务开发，该公司是一家新兴的生命科学公司，开发一类合成的诊断和治疗剂。2013年11月至2017年10月，Worsley先生担任Peregrine Pharmaceutical，Inc.（现Avid BioServices，Inc.）的业务发展Vice President，该公司是一家生物制药公司，开发免疫肿瘤相关抗体并制造生物制药产品。在加入Peregrine之前，Worsley先生曾在多家制药公司担任多个高级管理职位，其中包括Centrose Pharmaceutical，Inc.、Intrexon Corporation、Raven Biotechnologies，Inc.和Abgenix，Inc.。Worsley先生此前还曾在Peregrine Beijing，Ltd.的董事会任职。Worsley先生在犹他大学（University of Utah）获得国际经济与金融学学士学位，并在华盛顿大学（University of Washington）获得金融学工商管理硕士学位。
- Stephen T. Worsley has served as our Chief Business Officer since September 2018. From October 2017 to September 2018 Mr. Worsley served as Sr. Vice President, Business Development for Indi Molecular, Inc., an emerging life sciences company developing a synthetic class of diagnostic and therapeutic agents. From November 2013 to October 2017 Mr. Worsley served as Vice President of Business Development for Peregrine Pharmaceutical, Inc., now Avid BioServices, Inc, a biopharmaceutical company developing immuno-oncology related antibodies and manufacturing of biopharmaceutical products. Prior to Peregrine, Mr. Worsley held several senior management positions in various pharmaceutical companies, including Centrose Pharmaceutical, Inc., Intrexon Corporation, Raven Biotechnologies, Inc. and Abgenix, Inc. Mr. Worsley also previously served on the Board of Directors of Peregrine Beijing, Ltd. Mr. Worsley received a B.S. in International Economics and Finance from the University of Utah and an M.B.A. in Finance from the University of Washington.